InsiderTrades.com logo
Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
From Colonial Metals   |   Ad
Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…
Get Your Free Gold Guide

ANRO Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $9,852,683.40
Insider Selling (Last 12 Months): $0.00

Alto Neuroscience Insider Trading History Chart

This chart shows the insider buying and selling history at Alto Neuroscience by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Alto Neuroscience Share Price & Price History

Current Price: $4.72
Price Change: ▲ Price Increase of +0.19 (4.19%)
As of 11/14/2024 03:30 PM ET

This chart shows the closing price history over time for ANRO up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
From Colonial Metals   |   Ad
Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…
Get Your Free Gold Guide

Alto Neuroscience Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/9/2024Adam SavitzInsiderBuy12,069$12.60$152,069.4036,920View SEC Filing Icon  
3/28/2024Nicholas Conrad SmithCFOBuy6,150$16.36$100,614.0026,866View SEC Filing Icon  
2/6/2024Wave Global Lp AlphaMajor ShareholderBuy600,000$16.00$9,600,000.003,707,757View SEC Filing Icon  
See Full Table
Trump’s Back, but DC’s Coming for Your Money!
From Genesis Gold Group   |   Ad
Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…
Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov

SEC Filings (Institutional Ownership Changes) for Alto Neuroscience (NYSE:ANRO)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ANRO by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Alto Neuroscience Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/14/2024Vestal Point Capital LP650,000$7.44M0.6%+4.8%2.411%Search for SEC Filing on Google Icon
11/14/2024MetLife Investment Management LLC12,783$0.15M0.0%N/A0.047%Search for SEC Filing on Google Icon
11/13/2024BNP Paribas Financial Markets4,315$49K0.0%+619.2%0.016%Search for SEC Filing on Google Icon
11/13/2024FMR LLC2,363,056$27.03M0.0%+1.4%8.765%Search for SEC Filing on Google Icon
11/13/2024The Manufacturers Life Insurance Company 65,805$0.75M0.0%+84.5%0.244%Search for SEC Filing on Google Icon
11/13/2024Bowie Capital Management LLC19,484$0.22M0.0%-54.9%0.072%Search for SEC Filing on Google Icon
11/12/2024Charles Schwab Investment Management Inc.186,968$2.14M0.0%+182.5%0.694%Search for SEC Filing on Google Icon
11/12/2024Board of Trustees of The Leland Stanford Junior University79,740$0.91M0.1%-76.8%0.296%Search for SEC Filing on Google Icon
11/8/2024Jennison Associates LLC832,290$9.52M0.0%+80.3%3.087%Search for SEC Filing on Google Icon
8/19/2024Point72 Asset Management L.P.1,050,037$11.23M0.0%-6.7%3.906%Search for SEC Filing on Google Icon
8/14/2024Fred Alger Management LLC116,254$1.24M0.0%-1.5%0.432%Search for SEC Filing on Google Icon
8/8/2024Federated Hermes Inc.12,000$0.13M0.0%+33.3%0.045%Search for SEC Filing on Google Icon
8/6/2024Bowie Capital Management LLC43,186$0.46M0.0%N/A0.161%Search for SEC Filing on Google Icon
8/3/2024TD Asset Management Inc86,792$0.93M0.0%N/A0.323%Search for SEC Filing on Google Icon
8/1/2024Rhumbline Advisers10,539$0.11M0.0%N/A0.039%Search for SEC Filing on Google Icon
7/26/2024Bank of New York Mellon Corp23,557$0.25M0.0%N/A0.088%Search for SEC Filing on Google Icon
5/17/2024RA Capital Management L.P.1,385,491$21.27M0.3%N/A5.154%Search for SEC Filing on Google Icon
5/17/2024Artal Group S.A.350,000$5.37M0.1%N/A1.302%Search for SEC Filing on Google Icon
5/17/2024Zimmer Partners LP75,000$1.15M0.0%N/A0.279%Search for SEC Filing on Google Icon
5/16/2024AWM Investment Company Inc.299,147$4.59M0.6%N/A1.113%Search for SEC Filing on Google Icon
5/15/2024Price T Rowe Associates Inc. MD637,604$9.79M0.0%N/A2.372%Search for SEC Filing on Google Icon
5/10/2024Vanguard Group Inc.536,332$8.23M0.0%N/A1.995%Search for SEC Filing on Google Icon
5/2/2024Jennison Associates LLC458,599$7.04M0.0%N/A1.706%Search for SEC Filing on Google Icon
4/30/2024University of Texas Texas AM Investment Managment Co.22,175$0.34M0.1%N/A0.082%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Alto Neuroscience logo
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.
Read More on Alto Neuroscience

Today's Range

Now: $4.72
Low: $4.40
High: $4.72

50 Day Range

MA: $10.02
Low: $3.71
High: $14.52

52 Week Range

Now: $4.72
Low: $3.61
High: $24.00

Volume

390,819 shs

Average Volume

374,778 shs

Market Capitalization

$127.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Alto Neuroscience?

Alto Neuroscience's top insider shareholders include:
  1. Wave Global Lp Alpha (Major Shareholder)
  2. Adam Savitz (Insider)
  3. Nicholas Conrad Smith (CFO)
Learn More about top insider investors at Alto Neuroscience.

Who are the major institutional investors of Alto Neuroscience?

Alto Neuroscience's top institutional investors include:
  1. FMR LLC — 8.77%
  2. Jennison Associates LLC — 3.09%
  3. Vestal Point Capital LP — 2.41%
  4. Charles Schwab Investment Management Inc. — 0.69%
  5. Board of Trustees of The Leland Stanford Junior University — 0.30%
  6. The Manufacturers Life Insurance Company — 0.24%
Learn More about top institutional investors of Alto Neuroscience stock.

Which major investors are selling Alto Neuroscience stock?

Within the previous quarter, ANRO stock was sold by these institutional investors:
  1. Board of Trustees of The Leland Stanford Junior University
  2. Bowie Capital Management LLC

Which major investors are buying Alto Neuroscience stock?

During the previous quarter, ANRO stock was purchased by institutional investors including:
  1. Jennison Associates LLC
  2. Charles Schwab Investment Management Inc.
  3. FMR LLC
  4. The Manufacturers Life Insurance Company
  5. Vestal Point Capital LP
  6. MetLife Investment Management LLC
  7. BNP Paribas Financial Markets
In the previous year, these company insiders have bought Alto Neuroscience stock:
  1. Wave Global Lp Alpha (Major Shareholder)
  2. Adam Savitz (Insider)
  3. Nicholas Conrad Smith (CFO)
Learn More investors buying Alto Neuroscience stock.
Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
From Colonial Metals   |   Ad
Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…
Get Your Free Gold Guide